On the stock market since 2006, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 12% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
Sales run at $45.8M a year. A small number, but proof the product has real buyers.
The average analyst price target is $26.00 — 112% above today’s price.
It pays out $2.39 per share each year — regular cash for whoever holds the stock.
A loss of $0 against $45.8M in annual sales.
On our five-subject report card, PTMN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PTMN is a high-risk stock — not yet profitable, and its future rides on its product catching on.